Cargando…
Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma
We have made major advances in the treatment of melanoma through the use of targeted therapy and immune checkpoint blockade; however, clinicians are posed with therapeutic dilemmas regarding timing and sequence of therapy. There is a growing appreciation of the impact of antitumor immune responses t...
Autores principales: | Cooper, Zachary A., Reuben, Alexandre, Spencer, Christine N., Prieto, Peter A., Austin-Breneman, Jacob L., Jiang, Hong, Haymaker, Cara, Gopalakrishnan, Vancheswaran, Tetzlaff, Michael T., Frederick, Dennie T., Sullivan, Ryan J., Amaria, Rodabe N., Patel, Sapna P., Hwu, Patrick, Woodman, Scott E., Glitza, Isabella C., Diab, Adi, Vence, Luis M., Rodriguez-Canales, Jaime, Parra, Edwin R., Wistuba, Ignacio I., Coussens, Lisa M., Sharpe, Arlene H., Flaherty, Keith T., Gershenwald, Jeffrey E., Chin, Lynda, Davies, Michael A., Clise-Dwyer, Karen, Allison, James P., Sharma, Padmanee, Wargo, Jennifer A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4839346/ https://www.ncbi.nlm.nih.gov/pubmed/27141370 http://dx.doi.org/10.1080/2162402X.2015.1136044 |
Ejemplares similares
-
Molecular and immune heterogeneity in synchronous melanoma metastases
por: Reuben, Alexandre, et al.
Publicado: (2015) -
Pilot study of intratumoral (IT) cryoablation (cryo) in combination with systemic checkpoint blockade in patients with metastatic melanoma (MM)
por: Kim, Dae Won, et al.
Publicado: (2015) -
Intra-patient intra-tumoral immune heterogeneity is evident at progression on targeted therapy and immunotherapy for melanoma
por: Reuben, Alexandre, et al.
Publicado: (2014) -
Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma
por: Reuben, Alexandre, et al.
Publicado: (2017) -
Evidence of synergy with combined BRAF-targeted therapy and immune checkpoint blockade for metastatic melanoma
por: Cooper, Zachary A, et al.
Publicado: (2014)